Risk factors for and management of cognitive dysfunction in multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

http://www.wikidata.org/entity/Q33893669

about

Neurobehavioral burden of multiple sclerosis with nanotheranostics Functional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple Sclerosis Clinical correlates of grey matter pathology in multiple sclerosis Cognitive impairment in multiple sclerosis Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.Widespread age-related differences in the human brain microstructure revealed by quantitative magnetic resonance imaging.Noninvasive tongue stimulation combined with intensive cognitive and physical rehabilitation induces neuroplastic changes in patients with multiple sclerosis: A multimodal neuroimaging study Thalamus pathology in multiple sclerosis: from biology to clinical application.Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE Neural correlates of alerting and orienting impairment in multiple sclerosis patients.Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.Activities of daily living and lesion position among multiple sclerosis patients by Bayes network.Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.Occupational attainment as a marker of cognitive reserve in multiple sclerosis.The BDNF Val66Met polymorphism has opposite effects on memory circuits of multiple sclerosis patients and controls.Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis.Histamine H(3) receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibility Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study Fall Incidence as the Primary Outcome in Multiple Sclerosis Falls-Prevention Trials: Recommendation from the International MS Falls Prevention Research Network Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis.Cognitive-motor interference in multiple sclerosis: a systematic review of evidence, correlates, and consequences.Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease.Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study.Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.Information processing and magnetic resonance imaging indices of brain pathology in multiple sclerosis.Factors affecting employment among informal caregivers assisting people with multiple sclerosis.A Randomised Controlled Trial of Efficacy of Cognitive Rehabilitation in Multiple Sclerosis: A Cognitive, Behavioural, and MRI Study.Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.Treatment of cognitive impairment in multiple sclerosis: position paper.The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis.Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Ocular motor signatures of cognitive dysfunction in multiple sclerosis.DNA methylation in demyelinated multiple sclerosis hippocampus.

P2860

Q26778311-B71B15F4-5ED5-4C76-B511-771C31892217 Q26824972-843625A2-0D65-47F7-BEB9-4525AB2F1656 Q26999302-D3757069-F169-4B8C-A00F-E8D83ED34B55 Q28270988-9887900C-C773-449A-BBBD-C63C5B23E8D3 Q28281816-B119EBA2-EC8E-49B5-9273-FE10FDD43F2A Q28396785-F77D3A3A-7DB6-4DFB-85D1-5C057FA942A9 Q30524879-5E1AAE58-ABA2-4FD3-A507-B0809ECEFC7F Q30530185-BC9C19FA-C09B-4B1E-A4E3-A3B7FD4C366A Q30783478-914A737A-9C2A-43EE-BDE2-643574E1FBFB Q30855289-C4C3BB94-4E25-4303-803D-0EF2500105BB Q30871067-E91AAA61-AF25-4B70-AE4F-96440A143D20 Q33589940-2B36A8D2-963F-4CC1-9299-6B7AEF0DB2F1 Q33599348-4F57BFCF-6C79-412F-9457-911F4116807F Q33663751-028AC173-E7B3-41DC-B765-B6F9830DC44A Q33937065-F97482BA-3260-4B37-AEF4-C6BFB3E9F4B0 Q34338582-A6DF5EB5-ED5B-4469-A82E-AEEBE578EDB4 Q34448051-88A6ACA3-381E-4F43-8C51-AFB0D75DF84D Q34674567-336DA703-804C-48BF-A2F0-E25B1269215D Q34834179-59286DA5-0520-45C0-93D9-907C62F84DD5 Q34872216-C38AFA1F-25D9-43AB-9E47-A18A51ACF067 Q34926430-E954AB64-16D7-4F9D-94E5-8A1F25FE68F8 Q35063191-1B156875-0BFE-4BB6-9E9E-B3AA6D8D1EA9 Q35083857-31D2B6B3-F2EB-424A-A1B1-184D2A9594C4 Q35206796-FA374821-A41E-4E71-B899-4AFE4F42CEEE Q35672483-A97F944E-8E25-49E6-B40B-D6FF71B8026C Q36153283-D0806F90-243F-4932-BE8B-06D5015D5387 Q36597928-454BA4B6-A1E3-4916-AD0D-7731A8106807 Q36706010-92D202BA-A140-49E7-89F3-515FDA5D1B06 Q37178774-6191DD61-26E1-49AB-807E-F2BD18F15512 Q37442312-2524D39B-F117-4A32-A5C0-0A305D47A050 Q37442386-4947799D-6C95-45B6-9641-16811C585A7B Q37575546-E9D53DA0-0E58-4DF4-97BE-3D5634A6640B Q38028727-796CEAC2-7306-4157-AD3D-D6F6C4BB0C23 Q38049624-96201AD0-1B08-42BC-BB95-F140955E0E4D Q38062466-E66DDE95-7FCD-41FD-9595-7698941BC2BF Q38190349-CF1C9065-1AB1-40EC-B76D-9254082FD10A Q38238548-EA1EE6CB-E9C6-4006-9A66-23B6C272B89B Q38375605-AF7C8E62-9EDE-45C3-8D86-2AD2DB72DC82 Q38586620-67DEADA6-712C-4DF6-97E3-20EE44F37DBF Q38617952-2312F28D-F049-495B-B845-5C85DA1BDB01

P2860

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

http://www.wikidata.org/entity/Q33893669

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@ast

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@en

type

label

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@ast

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@en

prefLabel

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@ast

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@en

P1433

Q33893669-880D2CD1-0537-42A4-B6D9-D2941478020B

P1476

Q33893669-ABBFB796-E28B-4236-BF2C-D41AB62EB1FE

P2093

Q33893669-A9389BAD-97CC-4BB7-A135-BA759F4F2308

P2860

Q33893669-00BE0BA2-6B9F-424C-9C18-D8F6BFEEA081

Q33893669-03364B12-FE75-4AC3-98B5-69F53B39616C

Q33893669-035D1733-FED6-433C-9BAD-E63168F73A3A

Q33893669-07F531E1-C9B3-4C35-8966-5F7B1CE064A5

Q33893669-0892970E-2BCF-449A-9FEB-6DB2BB06AC72

Q33893669-08FDA90C-1BF9-456A-A66A-30AC5D2263A5

Q33893669-0947782B-E887-4F01-8294-751195CE76FF

Q33893669-098E34C6-59F3-4B2A-9391-91966E2BFDCE

Q33893669-0998E183-97FA-42F7-83A3-EF9B1F58F522

Q33893669-0ACE7526-9058-4863-A555-579E452B28EA

P2888

Q33893669-8E299AB2-C234-48F2-876C-AF6F1F436DAD

P304

Q33893669-910B06FC-3A22-4AC9-A03D-EDE6CEFE1C29

P31

Q33893669-9F4B6289-F385-4D55-9260-CC0A5FE41530

P356

Q33893669-6CEF003B-64D5-4D9A-BE21-999B6A6F519E

P407

Q33893669-E0DD7DE6-310C-4EEA-9E13-16C2C54EB8FB

P433

Q33893669-1A698AD0-AFC6-4ADE-B195-47D3A6A5EA30

P478

Q33893669-27FDAB5C-BB2B-48EA-AC59-35C38BD68F08

P50

Q33893669-48E9BF9F-F15F-4FC7-93CE-B0EA263AF0CE

P577

Q33893669-D8F48B06-FEE1-49C7-8EC6-0C7C2CB11DE6

P6179

Q33893669-126C1535-E79B-471B-A1D1-280AB9A2DA34

P698

Q33893669-5501FDEA-E71B-4222-93C6-BACFCFE60BEE

P921

Q33893669-53EBF1A2-20D0-4714-8D0D-343AE2C8B4A5

P356

NRNEUROL.2011.61

P1433

Nature Reviews Neurology

P1476

Risk factors for and management of cognitive dysfunction in multiple sclerosis.

@en

P2093

Ralph H B Benedict

http://www.w3.org/2001/XMLSchema#string

P2860

Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years

Apolipoprotein E: far more than a lipid transport protein

Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

Multiple sclerosis

Cognitive impairment in multiple sclerosis

Influence of education and occupation on the incidence of Alzheimer's disease

Axonal transection in the lesions of multiple sclerosis

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.

P2888

nrneurol.2011.61

P304

332-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEUROL.2011.61

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Robert Zivadinov

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052545701

http://www.w3.org/2001/XMLSchema#string

P698

21556031

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis